Sapan Shah, Ph.D., joined StrideBio as Chief Executive Officer in January 2019, and has led efforts to expand the company’s scientific platform, operations and external partnerships to support an innovative pipeline of engineered adeno-associated virus vectors and gene therapy products targeting rare disorders. Dr. Shah has spent the past 20 years as an advisor, entrepreneur, founder and chief executive working with innovative companies advancing novel therapeutics for areas of unmet medical need. Prior roles have included CEO of ARMGO Pharma, CEO of Shionogi Inc., Co-founder and Chairman of Ezose Sciences, Founder and CEO of Novatherx, Entrepreneur in Residence at Yale University and Associate Principal at McKinsey & Company. Dr. Shah holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University and B.A. degrees in Mathematics, Biochemistry, Molecular Biology and Cell Biology from the Integrated Science Program at Northwestern University.
Sapan Shah, Ph.D.
CHIEF EXECUTIVE OFFICER, STRIDEBIO